Latest News & Features
Americas
Despite the US Court of Appeals for the Federal Circuit’s ruling in Amgen v Sandoz, significant uncertainty concerning two key
provisions of the BPCIA remains, as Steve Coyle and Leslie-Anne Maxwell of Cantor Colburn describe. 27 October 2015
Americas
Non-profit organisation I-MAK is attempting to expose the problem at the heart of the patent system—that too often drug patents are wrongfully granted and consequently sick people in poorer countries are being left untreated. LSIPR delves deeper into the issues. 27 October 2015
Americas
Patent examiners not only have to tackle legal questions, but in cases of inventions directed to genetically modified animals they must consider moral issues too. This forms part of a wider controversial debate surrounding animals and patents. LSIPR reports. 27 October 2015
Asia
Despite the importance of traditional knowledge in many regions, an international treaty governing its control and exploitation does not exist yet—and talks have stalled. LSIPR reports. 27 October 2015
Americas
Lawyers have claimed that the latest ruling in Ariosa Diagnostics v Sequenom creates an “existential threat” to biomedical patents in the US, but is this really the case? LSIPR investigates. 27 October 2015
Americas
In July the US Court of Appeals for the Federal Circuit sought to clarify the rules on the ‘patent dance’, but with confusion reigning there are likely to be more twists and turns to come, as LSIPR finds out. 27 October 2015
Big Pharma
Being both an innovator and a generic drug company gives Teva a good view of the patent litigation landscape, as Galit Gonen, general counsel, Teva Europe, tells LSIPR. 27 October 2015
Americas
US-based Vertex Pharmaceuticals and CRISPR Therapeutics have agreed a research collaboration to discover and develop new treatments for genetic causes of human diseases. 26 October 2015
Americas
Biotechnology company Luc Therapeutics has agreed to licence its intellectual property covering its depression treatment to Novartis, stating that it will accelerate its programme into how to help people living with psychiatric diseases. 23 October 2015
Americas
Very few members of Congress are informed about the trajectory of section 101 and instead lawmakers are looking at ‘trolls’ and other patent issues, according to a counsel at the Biotechnology Industry Organization. 23 October 2015